4//SEC Filing
Bazemore Robert B 4
Accession 0000950170-25-036482
CIK 0001541157other
Filed
Mar 9, 8:00 PM ET
Accepted
Mar 10, 5:00 PM ET
Size
20.9 KB
Accession
0000950170-25-036482
Insider Transaction Report
Form 4
Bazemore Robert B
Director
Transactions
- Award
Series A Warrants (Right to Buy)
2025-03-06$1.12/sh+44,642$49,999→ 44,642 totalExercise: $0.87From: 2025-03-06Exp: 2026-03-06→ American Depositary Shares representing Ordinary Shares (44,642 underlying) - Award
Series B Warrants (Right to Buy)
2025-03-06$1.12/sh+44,642$49,999→ 44,642 totalExercise: $0.87From: 2025-03-06Exp: 2030-03-06→ American Depositary Shares representing Ordinary Shares (44,642 underlying) - Award
American Depositary Shares representing Ordinary Shares
2025-03-06$1.12/sh+44,642$49,999→ 44,642 total
Footnotes (2)
- [F1]Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
- [F2]On March 6, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.
Documents
Issuer
Akari Therapeutics Plc
CIK 0001541157
Entity typeother
Related Parties
1- filerCIK 0001620152
Filing Metadata
- Form type
- 4
- Filed
- Mar 9, 8:00 PM ET
- Accepted
- Mar 10, 5:00 PM ET
- Size
- 20.9 KB